<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084391</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0538</org_study_id>
    <nct_id>NCT05084391</nct_id>
  </id_info>
  <brief_title>Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)</brief_title>
  <official_title>Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I: For the Phase I portion, there will be up to 15 patients treated with SABR and&#xD;
      followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity&#xD;
      from SABR treatment. Efficacy as defined below will also be assessed. Following this Phase I&#xD;
      lead-in, results will be presented to the FDA for review. Only upon favorable analysis by the&#xD;
      FDA committee, and with written explicit permission, will the Phase II randomized portion&#xD;
      ensue. This is to act as a safety and efficacy safeguard and has is addressed more thoroughly&#xD;
      in the Statistical Analysis Plan of this protocol.&#xD;
&#xD;
      Phase II: A 1:1 randomized Phase II portion with 25 patients in each arm assigned to SABR or&#xD;
      current practice (standard of care; Figure 3). Standard of care is defined as nationally&#xD;
      recognized appropriate next treatment strategies for medical and catheter-ablation refractory&#xD;
      structural cardiac VT that is assessed and judged appropriate for the patient by his/her&#xD;
      treating cardiologist. This includes repeat catheter ablation (intravascular and/or&#xD;
      epicardial catheter ablation), placement of left-ventricular assist device (LVAD), heart&#xD;
      transplant, or further medical management (e.g. antiarrhythmic drug modulation/continuation).&#xD;
      Randomization will be performed through the Clinical Trial Conduct (CTC) website.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives Phase I:&#xD;
&#xD;
      -Assess acute toxicity and efficacy with SABR in treating refractory structural cardiac&#xD;
      ventricular tachyarrhythmias (VT). Ensure safety and treatment efficacy.&#xD;
&#xD;
      Primary Objectives Phase II:&#xD;
&#xD;
        -  Investigate overall toxicity with SABR compared to next best management practices&#xD;
           (standard of care) in treating refractory structural cardiac ventricular&#xD;
           tachyarrhythmias (VT).&#xD;
&#xD;
        -  Investigate VT episode reduction with SABR compared to standard of care to evaluate&#xD;
           effectiveness and potential superiority of SABR to current day options.&#xD;
&#xD;
      Primary Objectives Phase I:&#xD;
&#xD;
      1. Assess acute toxicity and efficacy with SABR in treating refractory structural cardiac&#xD;
      ventricular tachyarrhythmias (VT). Ensure safety and treatment efficacy.&#xD;
&#xD;
      Primary Objectives Phase II:&#xD;
&#xD;
        1. Investigate overall toxicity with SABR compared to next best management practices&#xD;
           (standard of care) in treating refractory structural cardiac ventricular&#xD;
           tachyarrhythmias (VT).&#xD;
&#xD;
        2. Investigate VT episode reduction with SABR compared to standard of care to evaluate&#xD;
           effectiveness and potential superiority of SABR to current day options.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      The following endpoints will be analyzed retrospectively based on prospectively collected&#xD;
      (event-free survival endpoints) and at the specified time points (e.g. QOL questionnaire).&#xD;
      Participation in QOL assessment and bio specimen collection for secondary endpoints is&#xD;
      completely voluntary and not mandated by the trial.&#xD;
&#xD;
        1. 6-month and 1-year overall survival (OS) of SABR compared to standard of care.&#xD;
&#xD;
        2. Quality of life (QOL) with SABR compared to standard of care (baseline and at 6 months&#xD;
           after randomization).&#xD;
&#xD;
        3. Hospitalization-free survival with SABR compared to standard of care (evaluated at&#xD;
           1-year).&#xD;
&#xD;
        4. Cost-effectiveness analysis with SABR compared to standard of care (evaluated at&#xD;
           1-year).&#xD;
&#xD;
        5. Freedom-from Antiarrhythmic medications with SABR compared to standard of care&#xD;
           (evaluated at 1-year).&#xD;
&#xD;
        6. Freedom-from Electrical Storm with SABR compared to standard of care (evaluated at&#xD;
           1-year).&#xD;
&#xD;
        7. Treatment-free Survival with SABR compared to standard of care (evaluated at 1-year).&#xD;
&#xD;
        8. Event-free Survival with SABR compared to standard of care (evaluated at 1-year).&#xD;
&#xD;
        9. Long term (&gt;1year) toxicity with SABR compared to standard of care (evaluated at&#xD;
           1-year).&#xD;
&#xD;
       10. Ejection fraction improvement with SABR compared to standard of care (evaluated at&#xD;
           1-year).&#xD;
&#xD;
       11. Transplant/LVAD-free survival with SABR compared to standard of care (evaluated at&#xD;
           1-year).&#xD;
&#xD;
       12. Number, type, and treatment success and cycle length of ICD-treated VTs with SABR&#xD;
           compared to standard of care (evaluated at 1-year).&#xD;
&#xD;
       13. Parameters obtained from cardiac imaging, and/or serum markers will be associated with&#xD;
           frequency of survival, response to treatment, and toxicity at regular time intervals&#xD;
           using cardiac ECHO, MRI, CT imaging, ICD interrogation, and/or serum/blood work studies&#xD;
           for prognostic/predictive biomarker and radiomic identification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall toxicity as assessed using CTCAE v4.0 will be used with SABR compared to next best management practices (standard of care) in treating refractory structural cardiac ventricular tachyarrhythmias (VT).</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Cardiac Arrhythmia</condition>
  <condition>Cardiac</condition>
  <condition>Ventricular Tachyarrhythmias</condition>
  <arm_group>
    <arm_group_label>Phase I:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I there will be up to 15 patients treated with SABR and followed for 6 months post-treatment to ensure no significant acute grade 3 or 4 toxicity from SABR treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II portion with 25 patients in each arm assigned to SABR or current practice (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stereotactic ablative radiotherapy (SABR)</intervention_name>
    <description>is safe for treating heart arrhythmias (irregular heartbeat</description>
    <arm_group_label>Phase I:</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Treatment</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Phase I:</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG 0-2&#xD;
&#xD;
          2. Age 18 years or older&#xD;
&#xD;
          3. Diagnosis of recurrent sustained monomorphic VT (MMVT) in the setting of structural&#xD;
             heart disease.&#xD;
&#xD;
          4. ICD placement and at least two (2) episodes of recurrencerecurrent sustained MMVT that&#xD;
             are terminated by anti-tachycardia pacing (ATP) or ICD shocks confirmed by device&#xD;
             interrogation in the preceding 3 months, since the last VT ablation procedure in&#xD;
             subjected who have failed catheter ablation.&#xD;
&#xD;
          5. Failed at least 1 anti-arrhythmic medication (not including beta-blockers) as&#xD;
             evidenced by persistent VT (including amiodarone and/or sotalol)&#xD;
&#xD;
          6. At least 1 attempted catheter ablation procedure with voltage and/or activation 3D&#xD;
             mapping. For patients with ischemic cardiomyopathy this would include failure of at&#xD;
             least one endocardial ablation performed at an experienced center. For patients with&#xD;
             non-ischemic cardiomyopathy, both endocardial and epicardial ablation should have been&#xD;
             attempted unless epicardial ablation/mapping is not feasible (e.g. patient tolerance,&#xD;
             deemed futile by EP, prior cardiac surgery).&#xD;
&#xD;
          7. Patients are eligible regardless of past or present oncologic history (however, please&#xD;
             refer to exclusion criterion #1 below, regarding life-expectancy of at least 12 months&#xD;
             in the absence of VT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unlikely to live at least 12 months in the absence of VT, as assessed by physicians&#xD;
&#xD;
          2. Heart failure dependent on ionotropes&#xD;
&#xD;
          3. Left ventricular assist device&#xD;
&#xD;
          4. Polymorphic VT&#xD;
&#xD;
          5. Ventricular fibrillation&#xD;
&#xD;
          6. 5 or more VT morphologies during stimulation testing suggestive of more than one&#xD;
             arrhythmogenic substrate&#xD;
&#xD;
          7. Prior radiation treatment to the chest for any reason&#xD;
&#xD;
          8. Last invasive catheter ablation attempt &lt;2 weeks&#xD;
&#xD;
          9. Lack of ICD data in preceding 3 months&#xD;
&#xD;
         10. Unable/unwilling to provide informed consent&#xD;
&#xD;
         11. Idiopathic VT&#xD;
&#xD;
         12. Women who are pregnant&#xD;
&#xD;
         13. Heart transplant&#xD;
&#xD;
         14. Active ischemia or other reversible causes of VT&#xD;
&#xD;
         15. Active non-cardiovascular illness or systemic infection&#xD;
&#xD;
         16. Cardiogenic shock&#xD;
&#xD;
         17. Presence of incessant VT that is hemodynamically unstable&#xD;
&#xD;
         18. Acute heart failure exacerbation&#xD;
&#xD;
         19. Revascularization in the past 30 days&#xD;
&#xD;
         20. Left ventricular ejection fraction &lt;15%&#xD;
&#xD;
         21. Scar tissue exceeding 80cc in volume planning treatment volume (PTV) ≥300cc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joe Chang</last_name>
    <phone>(713) 563-2337</phone>
    <email>jychang@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joe Change</last_name>
      <phone>713-563-2337</phone>
      <email>jychang@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Joe Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

